The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Aflibercept Biosimilars Market Research Report 2025
Synopsis
Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It is an inhibitor of vascular endothelial growth factor (VEGF).
Global Aflibercept Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Aflibercept Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Aflibercept Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer
Roche
Regeneron
Sanofi
Novartis
Sartorius
Amgen
Samsung Bioepis
Mylan
Formycon
Coherus BioSciences
Cadila Pharmaceuticals
Hetero
Biocon
Gene Techno Science
Qilu Pharmaceutical
Segment by Type
Intravitreal Injection
Intravenous Injection
Segment by Application
Wet Macular Degeneration
Metastatic Colorectal Cancer
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Aflibercept Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It is an inhibitor of vascular endothelial growth factor (VEGF).
Global Aflibercept Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Aflibercept Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Aflibercept Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer
Roche
Regeneron
Sanofi
Novartis
Sartorius
Amgen
Samsung Bioepis
Mylan
Formycon
Coherus BioSciences
Cadila Pharmaceuticals
Hetero
Biocon
Gene Techno Science
Qilu Pharmaceutical
Segment by Type
Intravitreal Injection
Intravenous Injection
Segment by Application
Wet Macular Degeneration
Metastatic Colorectal Cancer
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Aflibercept Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Aflibercept Biosimilars Market Overview
1.1 Product Overview and Scope of Aflibercept Biosimilars
1.2 Aflibercept Biosimilars Segment by Type
1.2.1 Global Aflibercept Biosimilars Market Value Comparison by Type (2023-2029)
1.2.2 Intravitreal Injection
1.2.3 Intravenous Injection
1.3 Aflibercept Biosimilars Segment by Application
1.3.1 Global Aflibercept Biosimilars Market Value by Application: (2023-2029)
1.3.2 Wet Macular Degeneration
1.3.3 Metastatic Colorectal Cancer
1.4 Global Aflibercept Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Aflibercept Biosimilars Revenue 2018-2029
1.4.2 Global Aflibercept Biosimilars Sales 2018-2029
1.4.3 Global Aflibercept Biosimilars Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Aflibercept Biosimilars Market Competition by Manufacturers
2.1 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2018-2023)
2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Aflibercept Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global Aflibercept Biosimilars Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Aflibercept Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Aflibercept Biosimilars, Product Type & Application
2.7 Aflibercept Biosimilars Market Competitive Situation and Trends
2.7.1 Aflibercept Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Aflibercept Biosimilars Players Market Share by Revenue
2.7.3 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Aflibercept Biosimilars Retrospective Market Scenario by Region
3.1 Global Aflibercept Biosimilars Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Aflibercept Biosimilars Global Aflibercept Biosimilars Sales by Region: 2018-2029
3.2.1 Global Aflibercept Biosimilars Sales by Region: 2018-2023
3.2.2 Global Aflibercept Biosimilars Sales by Region: 2024-2029
3.3 Global Aflibercept Biosimilars Global Aflibercept Biosimilars Revenue by Region: 2018-2029
3.3.1 Global Aflibercept Biosimilars Revenue by Region: 2018-2023
3.3.2 Global Aflibercept Biosimilars Revenue by Region: 2024-2029
3.4 North America Aflibercept Biosimilars Market Facts & Figures by Country
3.4.1 North America Aflibercept Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Aflibercept Biosimilars Sales by Country (2018-2029)
3.4.3 North America Aflibercept Biosimilars Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Aflibercept Biosimilars Market Facts & Figures by Country
3.5.1 Europe Aflibercept Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Aflibercept Biosimilars Sales by Country (2018-2029)
3.5.3 Europe Aflibercept Biosimilars Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Aflibercept Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Aflibercept Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Aflibercept Biosimilars Sales by Country (2018-2029)
3.6.3 Asia Pacific Aflibercept Biosimilars Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Aflibercept Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Aflibercept Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Aflibercept Biosimilars Sales by Country (2018-2029)
3.7.3 Latin America Aflibercept Biosimilars Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Aflibercept Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Aflibercept Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Aflibercept Biosimilars Sales by Country (2018-2029)
3.8.3 Middle East and Africa Aflibercept Biosimilars Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Aflibercept Biosimilars Sales by Type (2018-2029)
4.1.1 Global Aflibercept Biosimilars Sales by Type (2018-2023)
4.1.2 Global Aflibercept Biosimilars Sales by Type (2024-2029)
4.1.3 Global Aflibercept Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global Aflibercept Biosimilars Revenue by Type (2018-2029)
4.2.1 Global Aflibercept Biosimilars Revenue by Type (2018-2023)
4.2.2 Global Aflibercept Biosimilars Revenue by Type (2024-2029)
4.2.3 Global Aflibercept Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global Aflibercept Biosimilars Price by Type (2018-2029)
5 Segment by Application
5.1 Global Aflibercept Biosimilars Sales by Application (2018-2029)
5.1.1 Global Aflibercept Biosimilars Sales by Application (2018-2023)
5.1.2 Global Aflibercept Biosimilars Sales by Application (2024-2029)
5.1.3 Global Aflibercept Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global Aflibercept Biosimilars Revenue by Application (2018-2029)
5.2.1 Global Aflibercept Biosimilars Revenue by Application (2018-2023)
5.2.2 Global Aflibercept Biosimilars Revenue by Application (2024-2029)
5.2.3 Global Aflibercept Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global Aflibercept Biosimilars Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer Aflibercept Biosimilars Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Roche Aflibercept Biosimilars Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Regeneron
6.3.1 Regeneron Corporation Information
6.3.2 Regeneron Description and Business Overview
6.3.3 Regeneron Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Regeneron Aflibercept Biosimilars Product Portfolio
6.3.5 Regeneron Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Aflibercept Biosimilars Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novartis Aflibercept Biosimilars Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Sartorius
6.6.1 Sartorius Corporation Information
6.6.2 Sartorius Description and Business Overview
6.6.3 Sartorius Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sartorius Aflibercept Biosimilars Product Portfolio
6.6.5 Sartorius Recent Developments/Updates
6.7 Amgen
6.6.1 Amgen Corporation Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Aflibercept Biosimilars Product Portfolio
6.7.5 Amgen Recent Developments/Updates
6.8 Samsung Bioepis
6.8.1 Samsung Bioepis Corporation Information
6.8.2 Samsung Bioepis Description and Business Overview
6.8.3 Samsung Bioepis Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Samsung Bioepis Aflibercept Biosimilars Product Portfolio
6.8.5 Samsung Bioepis Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Mylan Aflibercept Biosimilars Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Formycon
6.10.1 Formycon Corporation Information
6.10.2 Formycon Description and Business Overview
6.10.3 Formycon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Formycon Aflibercept Biosimilars Product Portfolio
6.10.5 Formycon Recent Developments/Updates
6.11 Coherus BioSciences
6.11.1 Coherus BioSciences Corporation Information
6.11.2 Coherus BioSciences Aflibercept Biosimilars Description and Business Overview
6.11.3 Coherus BioSciences Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Coherus BioSciences Aflibercept Biosimilars Product Portfolio
6.11.5 Coherus BioSciences Recent Developments/Updates
6.12 Cadila Pharmaceuticals
6.12.1 Cadila Pharmaceuticals Corporation Information
6.12.2 Cadila Pharmaceuticals Aflibercept Biosimilars Description and Business Overview
6.12.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Cadila Pharmaceuticals Aflibercept Biosimilars Product Portfolio
6.12.5 Cadila Pharmaceuticals Recent Developments/Updates
6.13 Hetero
6.13.1 Hetero Corporation Information
6.13.2 Hetero Aflibercept Biosimilars Description and Business Overview
6.13.3 Hetero Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Hetero Aflibercept Biosimilars Product Portfolio
6.13.5 Hetero Recent Developments/Updates
6.14 Biocon
6.14.1 Biocon Corporation Information
6.14.2 Biocon Aflibercept Biosimilars Description and Business Overview
6.14.3 Biocon Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Biocon Aflibercept Biosimilars Product Portfolio
6.14.5 Biocon Recent Developments/Updates
6.15 Gene Techno Science
6.15.1 Gene Techno Science Corporation Information
6.15.2 Gene Techno Science Aflibercept Biosimilars Description and Business Overview
6.15.3 Gene Techno Science Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Gene Techno Science Aflibercept Biosimilars Product Portfolio
6.15.5 Gene Techno Science Recent Developments/Updates
6.16 Qilu Pharmaceutical
6.16.1 Qilu Pharmaceutical Corporation Information
6.16.2 Qilu Pharmaceutical Aflibercept Biosimilars Description and Business Overview
6.16.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Qilu Pharmaceutical Aflibercept Biosimilars Product Portfolio
6.16.5 Qilu Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Aflibercept Biosimilars Industry Chain Analysis
7.2 Aflibercept Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Aflibercept Biosimilars Production Mode & Process
7.4 Aflibercept Biosimilars Sales and Marketing
7.4.1 Aflibercept Biosimilars Sales Channels
7.4.2 Aflibercept Biosimilars Distributors
7.5 Aflibercept Biosimilars Customers
8 Aflibercept Biosimilars Market Dynamics
8.1 Aflibercept Biosimilars Industry Trends
8.2 Aflibercept Biosimilars Market Drivers
8.3 Aflibercept Biosimilars Market Challenges
8.4 Aflibercept Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
